Search results
Results from the WOW.Com Content Network
Clofazimine also showed a dosage-dependent inhibition of neutrophil motility, lymphocyte transformation, [19] mitogen-induced PBMC proliferation [20] and complement-mediated solubilization of pre-formed immune complexes in vitro. [21] A mechanistic studying of clofazimine in human T cells revealed that this drug is a Kv1.3 channel blocker. [22]
Dapsone is commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. [4] It is also used to both treat and prevent pneumocystis pneumonia (PCP). [ 4 ] [ 10 ] It is also used for toxoplasmosis in people unable to tolerate trimethoprim with sulfamethoxazole .
16491 Ensembl ENSG00000177272 ENSMUSG00000047959 UniProt P22001 P16390 RefSeq (mRNA) NM_002232 NM_008418 RefSeq (protein) NP_002223 NP_032444 Location (UCSC) Chr 1: 110.67 – 110.67 Mb Chr 3: 106.94 – 106.95 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Potassium voltage-gated channel, shaker-related subfamily, member 3, also known as KCNA3 or K v 1.3, is a protein that in ...
This mechanism involves the direct effects of antipsychotic drugs on glutamate receptors. By using the technique of functional neurochemical assay chlorpromazine and phenothiazine derivatives have been shown to have inhibitory effects on NMDA receptors that appeared to be mediated by action at the Zn site. It was found that there is an increase ...
The mechanism of action is thought to be through disruption of mycolic acid. [5] [18] Expression of the ethA gene is controlled by ethR, a transcriptional repressor. It is thought that improving ethA expression will increase the efficacy of ethionamide and prompting interest by drug developers in EthR inhibitors as a co-drug. [4]
Lomustine is an alkylating chemotherapy drug that is indicated by the FDA for the treatment of patients with brain tumors (primary and metastatic), following any necessary surgery and radiation, as well as for treatment of progressive Hodgkin’s lymphoma. [8]
Xanomeline is an agonist that primarily targets the muscarinic acetylcholine receptor family of five muscarinic receptor subtypes, which are designated M 1-M 5. [2] While it binds with near identical affinity to all five of the muscarinic receptor subtypes as measured by displacement of a muscarinic radioligand, the preponderance of evidence suggests that xanomeline acts preferentially in the ...
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects.